Serodus (SER)

Executive Summary

Serodus is a Norwegian biotechnology company focused on developing novel therapies to delay the need for dialysis in patients with diabetic kidney disease (DKD). Founded in 2001 and headquartered in Oslo, the company operates with two drug candidates: SER150 and SER140, each targeting DKD through distinct mechanisms of action. While the specific development stage of these candidates is undisclosed, Serodus addresses a significant unmet medical need in Type 2 diabetes-related kidney disease. With a valuation of approximately $26.7 million and private status, the company is relatively early-stage but benefits from a clear therapeutic focus and potential for differentiated treatment options. The DKD market is large and growing, but development timelines are long and competitive. Serodus lacks publicly available clinical data or recent milestones, creating uncertainty around progress. Conviction is moderate, reflecting the promise of its dual-target strategy against the risks typical of early-stage biotech. Near-term catalysts could include clinical trial initiations, preclinical data releases, or partnership announcements that validate the pipeline and provide funding runway.

Upcoming Catalysts (preview)

• Q4 2026Initiation of a Phase 1/2 clinical trial for SER15045% success
• Q1 2027Presentation of preclinical data for SER140 at a medical conference55% success
• Q2 2027Announcement of a strategic partnership or licensing deal30% success